ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Prolonged Maintenance with Bevacizumab (BOOST Trial) with Jacobus Pfisterer and Philipp Harter"
Episode Synopsis
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Professors Jacobus Pfisterer and Philipp Harter to discuss prolonged maintenance with bevacizumab. Prof. Philipp Harter is the director of the Department of Gynecology & Gynecologic Oncology at Kliniken Essen-Mitte in Essen, Germany and the chair of the AGO Study Group. Prof. Jacobus Pfisterer is Director of the Gynecologic Oncology Center in Kiel Germany and former chair of the AGO Study Group.
Highlights:
- 30-month bevacizumb maintenance does not improve progression-free survival nor overall survival in advanced ovarian cancer.
- 30-month bevacizumb maintenance is associated with more adverse events compared to 15 months.
- 15-month bevacizumb maintenance remains standard of care.
Highlights:
- 30-month bevacizumb maintenance does not improve progression-free survival nor overall survival in advanced ovarian cancer.
- 30-month bevacizumb maintenance is associated with more adverse events compared to 15 months.
- 15-month bevacizumb maintenance remains standard of care.
More episodes of the podcast BMJ talk medicine
Primary Survey - the highlights of June 2023
02/06/2023
Aciclovir PEP after VZ exposure in pregnancy, falls and fractures with aspirin, an inclisiran rant
31/05/2023
Atoms: the highlights from the ADC June 2023
26/05/2023
Quantity AND Quality Is Key For People With Knee OA – Dr Kerry Costello And Dr Deepak Kumar. EP#531
26/05/2023
Editors Highlights of the June 2023 issue
25/05/2023
How to model safe clinical practice
23/05/2023
In God we trust